Chemistry:BMS-986278
From HandWiki
Short description: Chemical compound
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H31N5O5 |
Molar mass | 445.520 g·mol−1 |
3D model (JSmol) | |
| |
|
BMS-986278 is an experimental small-molecule drug and lysophosphatidic acid receptor 1 (LPA1) antagonist developed by Bristol Myers Squibb for idiopathic pulmonary fibrosis.[1][2][3]
References
- ↑ Murphy, Brian; Sum, Chi-Shing; Wang, Tao; Heiry, Rebekah; Kalinowski, Stephen; Hung, Chen-Pin; Chu, Ching-Hsuen; Azzara, Anthony et al. (28 September 2019). "LPA1 antagonist BMS-986278 for idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation". Idiopathic interstitial pneumonias. pp. PA5383. doi:10.1183/13993003.congress-2019.PA5383.
- ↑ Cheng, Peter T. W.; Kaltenbach, Robert F.; Zhang, Hao; Shi, Jun; Tao, Shiwei; Li, Jun; Kennedy, Lawrence J.; Walker, Steven J. et al. (11 November 2021). "Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases". Journal of Medicinal Chemistry 64 (21): 15549–15581. doi:10.1021/acs.jmedchem.1c01256. PMID 34709814.
- ↑ Corte, Tamera J; Lancaster, Lisa; Swigris, Jeffrey J; Maher, Toby M; Goldin, Jonathan G; Palmer, Scott M; Suda, Takafumi; Ogura, Takashi et al. (December 2021). "Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)". BMJ Open Respiratory Research 8 (1): e001026. doi:10.1136/bmjresp-2021-001026. PMID 34969771.
Original source: https://en.wikipedia.org/wiki/BMS-986278.
Read more |